American Society of Hematology

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.

Content to be used in accordance with local CPO guidelines

SCD

SCD

List of Presentations

CAR-T CML Early Pipeline ITP/SAA LCH MDS/AML/AdvSM MPN/GvHD PNH SCD

Frequency of Vaso-Occlusive Crises Is Associated With Health-Related Quality of Life in Pediatric Patients With Sickle Cell Disease: US Cross-Sectional Surveys of Adolescents and Caregivers

Campbell A

  • Presentation # 490 – Oral
    December 12, 2021 | 12:45 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Initial Safety and Efficacy Results From the Phase II, Multicenter, Open-Label SOLACE-Kids Trial of Crizanlizumab in Adolescents With Sickle Cell Disease (SCD)

Heeney M

  • Presentation # 12 – Oral
    December 11, 2021 | 10:45 AM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Association Between Hospitalised Vaso-Occlusive Crises and Acute/Chronic Complications in Sickle Cell Disease Patients Aged 16 Years and Older Using the French National Health Insurance Database (SNDS)

Arlet J

  • Presentation # 3107 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Sickle Cell Disease Mortality in Brazil: Real-World Evidence

Cançado R

  • Presentation # 3025 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

The Increased Burden of Sickle Cell Disease in Italy: Findings From the GREATalyS (Generating Real world Evidence Across ITALy in SCD) Study

De Franceschi

  • Presentation # 1950 – Poster
    December 11, 2021 | 05:30 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Children in the United States With Sickle Cell Disease Experience Greater Educational Burden Than Those Living in Low/Middle Income and Other High-Income Countries

El Rassi

  • Presentation # 3106 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Association of Hospitalization Due to Vaso-Occlusive Crisis With Subsequent Sickle Cell Disease-Related Organ Damage Hospitalization: Retrospective Analysis of 3-Year Observational Study Data

Heeney M

  • Presentation # 2037 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Rare Cases of Infusion-Related Reactions (IRRs) Presenting As Pain Events During or After Crizanlizumab Infusion in Patients (Pts) With Sickle Cell Disease (SCD): A Systematic Evaluation of Post-Marketing (PM) Reports

Kanter J

  • Presentation # 3112 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Early Evaluation of the Use of Crizanlizumab in Sickle Cell Disease: A National Alliance of Sickle Cell Centers Study

Kanter J

  • Presentation # 3113 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Sickle Cell Disease in Sweden – Prevalence and Resource Use Estimated Through Population-Based National Registers

Kjellander C

  • Presentation # 2040 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Pediatric Hydroxyurea Treatment Patterns, Sickle Cell Disease-Related Complication Rates, and Costs in a Large US Administrative Claims Database: A Retrospective Analysis

Manwani D

  • Presentation # 4055 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Experiences of Sickle Cell Disease (SCD) Reported by Healthcare Professionals (HCPs) Across Different Regions: International Sickle Cell World Assessment Survey (SWAY)

Osunkwo I

  • Presentation # 3026 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Characterization of Two Anti-P-Selectin Monoclonal Antibodies (mAbs): Crizanlizumab Shows Comparable or Stronger Effects Versus Inclacumab Across Cell Adhesion Assays In Vitro

Rubic-Schneider T

  • Presentation # 2032 – Poster
    December 12, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Effect of Crizanlizumab and Standard of Care (SoC) Versus Standard of Care Alone on Renal Function in Patients With Chronic Kidney Disease Due to Sickle Cell Nephropathy (STEADFAST)

Saraf S

  • Presentation # 3096 – Poster
    December 13, 2021 | 06:00 PM EST

  • Abstract
This presentation will be available once the congress embargo lifts

Real-World Data on the Occurrence of Vaso-Occlusive Crises (VOCs) in Patients With Sickle Cell Disease (SCD) and a High Baseline Disease Burden Treated With Crizanlizumab: Results From a Managed Access Program (MAP)

Cançado R

  • Presentation # 4180 – Publication Only

  • Abstract
This presentation will be available once the congress embargo lifts
View list of select presentations for this compound